Advanced search
Publication Cover
Drug Delivery Volume 25, 2018 - Issue 1
Submit an article Journal homepage
3,269
Views
24
CrossRef citations to date
0
Altmetric
Research Article

Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy

Jincheng YangSchool of Pharmaceutical Engineering, and Key Laboratory of Structure-Based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang, P. R. China; View further author information
,
Qingzhi LvDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, P. R. ChinaView further author information
,
Wei WeiDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, P. R. ChinaView further author information
,
Zhengtao YangSchool of Pharmaceutical Engineering, and Key Laboratory of Structure-Based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang, P. R. China; View further author information
,
Jiajun DongSchool of Pharmaceutical Engineering, and Key Laboratory of Structure-Based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang, P. R. China; View further author information
,
Ruoshi ZhangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, P. R. ChinaView further author information
,
Qiming KanDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, P. R. ChinaView further author information
,
Zhonggui HeDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, P. R. ChinaCorrespondence[email protected]
View further author information
&
Youjun XuSchool of Pharmaceutical Engineering, and Key Laboratory of Structure-Based Drug Design & Discovery (Ministry of Education), Shenyang Pharmaceutical University, Shenyang, P. R. China; Correspondence[email protected]
View further author information
 show all
Pages 807-814 | Received 17 Jan 2018, Accepted 09 Mar 2018, Published online: 19 Mar 2018

References

  • Chuan X, Song Q, Lin J, et al. (2014). Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)–drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo. Mol Pharmaceutics 11:3656–70.
  • Colby AH, Liu R, Schulz MD, et al. (2016). Two-step delivery: exploiting the partition coefficient concept to increase intratumoral paclitaxel concentrations in vivo using responsive nanoparticles. Sci Rep 6:18720.
  • Elsadek B, Kratz F. (2012). Impact of albumin on drug delivery-new applications on the horizon. J Control Release 157:4–28.
  • Gordaliza M. (2007). Natural products as leads to anticancer drugs. Clin Transl Oncol 9:767–76.
  • Han J, Michel AR, Lee HS, et al. (2015). Nanoparticles containing high loads of paclitaxel-silicate prodrugs: formulation, drug release, and anticancer efficacy. Mol Pharmaceutics 12:4329–35.
  • He Z, Wan X, Schulz A, et al. (2016). A high capacity polymeric micelle of paclitaxel: implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials 101:296–309.
  • Jahangirian H, Lemraski EG, Webster TJ, et al. (2017). A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine. Int J Nanomedicine 12:2957–78.
  • Jordan MA, Wilson L. (2004). Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–65.
  • Kratz F. (2011). INNO-206 (DOXO-EMCH), an albumin-binding prodrug of doxorubicin under development for phase II studies. Curr Bioact Compd 7:33–8.
  • Kratz F, Azab S, Zeisig R, et al. (2013). Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model. Int J Pharm 441:499–506.
  • Kratz F, Elsadek B. (2012). Clinical impact of serum proteins on drug delivery. J Control Release 161:429–45.
  • Kratz F, Warnecke A, Scheuermann K, et al. (2002). Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 45:5523–33.
  • Lian H, Sun J, Yu YP, et al. (2011). Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery. Int J Nanomedicine 6:3323.
  • Liu Y, Sun J, Cao W, et al. (2011). Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm. 421:160–9.
  • Liu Y, Sun J, Lian H, et al. (2014). Folate and CD44 receptors dual‐targeting hydrophobized hyaluronic acid paclitaxel‐loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J Pharm Sci 103:1538–47.
  • Luo C, Sun J, Liu D, et al. (2016a). Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett 16:5401–8.
  • Luo C, Sun J, Sun B, et al. (2016b). Facile fabrication of tumor redox‐sensitive nanoassemblies of small‐molecule oleate prodrug as potent chemotherapeutic nanomedicine. Small 12:6353–62.
  • Malonga H, Neault J, Diamantoglou S, et al. (2005). Taxol anticancer activity and DNA binding. Mini-Rev Med Chem 5:307–11.
  • Ramasamy T, Ruttala HB, Gupta B, et al. (2017). Smart chemistry-based nanosized drug delivery systems for systemic applications: a comprehensive review. J Control Release 258:226–53.
  • Satsangi A, Roy SS, Satsangi RK, et al. (2014). Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. Mol Pharmaceutics 11:1906–18.
  • Wang Y, Liu D, Zheng Q, et al. (2014). Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines. Nano Lett 14:5577–83.
  • Wohl AR, Michel AR, Kalscheuer S, et al. (2014). Silicate esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential. J Med Chem 57:2368–79.
  • Xiao W, Suby N, Xiao K, et al. (2017). Extremely long tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer. J Control Release 264:169–79.
  • Zhong Y, Goltsche K, Cheng L, et al. (2016). Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials 84:250–61.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.